Form 4 Filing for Robert E. Landry

Robert E. Landry, a director at CYTOKINETICS INC (CYTK), acquired 2,851 shares of Common Stock on May 27, 2026, with no cost basis, increasing his direct holdings to 10,184 shares. Additionally, Landry was granted 4,301 Non-Qualified Stock Options to buy Common Stock, exercisable from June 27, 2026, to May 26, 2036, with an exercise price of $77.15 per share. These options, also held directly, bring his total post-transaction direct ownership to 4,301 shares.